Vaccine boosts response to IL-2

June 8, 2011

A GP100 peptide vaccine can significantly enhance response to the immune activator interleukin-2 in patients with advanced melanoma, MedPage Today reports.

Goshen, Ind. - A GP100 peptide vaccine can significantly enhance response to the immune activator interleukin-2 in patients with advanced melanoma, MedPage Today reports.

Researchers from the Indiana University Health Goshen Center for Cancer Care randomly assigned 185 patients with stage 4 or locally advanced stage 3 cutaneous melanoma to receive interleukin-2 alone or interleukin-2 plus the GP100 peptide vaccine. Investigators found that about one in six responded to the vaccine when it was combined with interleukin-2. In contrast, only about one patient in 17 responded to interleukin-2 alone.

The vaccine also slowed the disease’s progression, suggesting that the vaccine might improve overall survival. Median overall survival was 17.8 months for the vaccine patients compared with 11.1 months for those receiving only interleukin-2, although the difference did not reach significance.

The study appears in the June 2 issue of the New England Journal of Medicine.